Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc, filed a statement of changes in beneficial ownership on November 3, 2026, disclosing an acquisition of deferred stock units dated October 30, 2026.

Key Highlights

  • Reporting person: Jeffrey N. Simmons, identified in the filing as President, CEO, and Director of Elanco Animal Health Inc (NYSE:ELAN).
  • Transaction: Acquisition (code A) of 122.5902 Deferred Stock Units on October 30, 2026.
  • Price per unit: $23.06, as reported in the filing.
  • Post-transaction holdings: Simmons beneficially owned 25,741.9123 Deferred Stock Units following the transaction, held directly.
  • Unit structure: Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
  • Settlement terms: Units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.

Simmons DSU Acquisition Under Elanco's Executive Deferral Plan

According to the filing, Jeffrey N. Simmons acquired 122.5902 Deferred Stock Units in Elanco Animal Health Inc on October 30, 2026, at a price of $23.06 per unit. The transaction was recorded under Table II, covering derivative securities, and was coded as an acquisition. The units are held directly by the reporting person.

Elanco Animal Health Inc is an animal health company incorporated and headquartered at 450 Elanco Circle, Indianapolis, Indiana 46221. Its common stock trades on the New York Stock Exchange under the ticker ELAN. The filing notes that each deferred stock unit carries the right to receive one share of Company common stock or its cash equivalent, linking the derivative instruments directly to the underlying equity. Following this acquisition, Simmons held a total of 25,741.9123 Deferred Stock Units on a direct basis, according to the disclosure.

The filing states that settlement of the deferred stock units occurs "in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan." The statement of changes in beneficial ownership was signed by Amy C. Seidel as Attorney-in-Fact for Jeffrey N. Simmons and filed with the SEC on November 3, 2026. No non-derivative securities transactions were reported in Table I of this filing.

What Was Disclosed

The filing disclosed an October 30, 2026 acquisition of 122.5902 Deferred Stock Units by Elanco Animal Health's President and CEO, Jeffrey N. Simmons, at $23.06 per unit, bringing his total direct beneficial ownership of such units to 25,741.9123.